China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.…
China SXT Pharmaceuticals, Inc. Announces Share Consolidation
China SXT Pharmaceuticals (NASDAQ: SXTC) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 56 employees.
The shares were at 2.645 USD on 20 November 2026, down 100.0% over 52 weeks. Its 52-week range is 2.521 USD to 8376000.00 USD: the price is 100.0% below the high and 4.9% above the low.
Its market capitalisation is 273.95K USD.
China SXT Pharmaceuticals reports return on equity of -20.9% and revenue down 43.9% year over year.
It holds more cash than debt, a net cash position of 27.20M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.
No upcoming events tracked.